02xl is your source for accurate and trustworthy information so you can make the best choices for your health and wellness.
PS: Please note that 02xl provides this information for the benefit of the rare disease and overweight community. 02xl is not a medical provider or health care facility and thus can neither diagnose any disease or disorder nor endorse or recommend any specific medical treatments. Patients must rely on the personal and individualized medical advice of their qualified health care professionals before seeking any information related to their particular diagnosis, cure or treatment of a condition or disorder.
– Results from Phase 2b ReNeu trial of mirdametinib in NF1-PN accepted for oral presentation –
– Additional data from the Phase 3 DeFi trial of OGSIVEO (nirogacestat) in adults with desmoid tumors also accepted for presentations at ASCO –